Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.

This analysis identified factors associated with successful cessation of biologics for remission in JIA as absence of uveitis, prior treatment with tocilizumab and starting biologics earlier in the disease course. Further research is needed to guide clinical recommendations.